title: [Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation].
abstract: To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy.
  
  
  
  The disease relapsed in 14 hepatitis B patients with decompensated liver cirrhosis during lamivudine treatment due to the YMDD motif mutation. All 14 patients had positive HVBDNA and active hepatitis, and were evaluated as Child-Pugh Score C (CPS-C). The patients were treated with lamivudine 50 mg/d and adefovir dipivoxil 10 mg/d for 6 months.
  
  
  
  One patient signed off due to non-hypoxemic hyperlactacidemia; other 13 patients showed decreased serum HBVDNA. All patients had serum HBVDNA < or =10(5) copies/ml and 7 patients had HBVDNA < or =10(4) copies/ml. Six patients regained normal serum ALT level and Child-Pugh scores decreased in all patients.
  
  
  
  Adefovir dipivoxil has satisfied efficacy and safety in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine treatment.
authors.affiliation: Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China.
authors.forename: Guan-guan
authors.initials: GG
authors.lastname: Su
authors.forename: Nian-fen
authors.initials: NF
authors.lastname: Zhao
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhou
authors.forename: Mei-fang
authors.initials: MF
authors.lastname: Ying
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D020816:Amino Acid Motifs / Q000235:genetics; D000998:Antiviral Agents / Q000627:therapeutic use; D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000235:genetics* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D063065:Organophosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D017434:Protein Structure, Tertiary / Q000235:genetics; D012008:Recurrence; D048348:Reverse Transcription / Q000235:genetics
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D019259:Lamivudine; D004259:DNA-Directed DNA Polymerase; D000225:Adenine; C106812:adefovir dipivoxil